Treatment with SDC2 protected mice from the development of bleomycin-induced lung fibrosis in the inflammatory arthritis mouse model and tended to decrease bronchoalveolar fluid levels of IL-6. The gene discussed is IL6; the disease is pulmonary fibrosis.